Complementary Alternative Cardiovascular Medicine

118 Alternative Cardiovascular Medicine
26. Langsjoen PH, Langsjoen PH, Folkers K. Isolated diastolic dysfunction of the
myocardium and its response to CoQ10 treatment. Clin Invest 1993;71:S140–144.
27. Hoffman-Bang C, Rehnqvist N, Swedberg K, Astrom H. Coenzyme Q 10 as an adjunctive
in treatment of congestive heart failure. Am J Cardiol 1992;19(Suppl):216A.
28. Folkers K, Langsjoen PH, Langsjoen PH. Therapy with coenzyme Q 10 of patients
in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res
Comm 1992;182:247–253.
29. Baggio E, Gandini R, Placher AC, Passeri M, Carmosino G. Italian multicenter study
on safety and efficacy of coenzyme Q 10. Mol Aspect Med 1994;15:S287–S294.
30. Hoffman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H for the CoQ 10
study group. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive
heart failure. J Card Fail 1995;1:101–107.
31. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q 10 in patients
with congestive heart failure. Ann Intern Med 2000;132:636–640.
32. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect
of coenzyme Q 10 on left ventricular function in patients with congestive heart failure.
J Am Coll Cardiol 1999;33:1549–1552.
33. Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N. Effects of
coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol
1985;56:247–251.
34. Judy WV, Stogsdill WW, Folkers K. Myocardial preservation by therapy with
coenzyme Q 10 during heart surgery. Clin Investig 1993;71:S155–161.
35. Chen YF, Lin YT, Wu SC. Effectiveness of coenzyme Q 10 on myocardial preservation
during hypothermic cardioplegic arrest. J Thorac Cardiovasc Surg
1994;107:242–247.
36. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog
Cardiovasc Dis 1997;40:265–286.
37. Rebuzzi AG, Schiavoni G, Amico CM, et al. Beneficial effect of L-carnitine in the
reduction of nectrotic area in acute myocardial infarction. Drugs Exp Clin Res
1984;10:219–223.
38. Iliceto S, Scrutinio D, Bruzzi P, et al. Effect of L-carnitine administration on left
ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine
Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol
1995;26:380–387.
39. Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic
efficacy in post-infarction. Drugs Exp Clin Res 1992;18:335–365.
40. Corbucci GG, Menichetti A, Cogliatti A, Nicoli P, Ruvolo C. Metabolic aspects of
acute tissue hypoxia during extracorporeal circulation and their modification induced
by L-carnitine treatment. Int J Clin Pharmacol Res 1992;12:149–157.
41. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the
therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure.
Arzneimittel-Forschung 1992;42:1101–1104.
42. De Giuli F, Pasini E, Opasich C, Mazzoletti A, Ferrari R. Effects of propionyl-Lcarnitine
in patients with heart failure (abstract). J Mol Cell Cardiol 1995;27:V44.
43. Romagnoli GF, Naso A, Carraro G, Lidestri V. Beneficial effects of L-carnitine in
dialysis patients with impaired left ventricular function; an observational study.
Curr Med Res Opin 2002;18:172–175.
44. Ghidini O, Azzuro M, Vita G, Sartori G. Evaluation of therapeutic efficacy of L-carnitine
in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1988;26:217–220.